BIOMAT Database Logo BIOMAT Database Logo

Third-line chemotherapy with mitomycin, vinblastine, and carmustine (BCNU) in refractory breast carcinoma: a pilot study. 1982

A Veronesi, and U Tirelli, and E Galligioni, and M G Trovò, and D Crivellari, and M Donatella Magri, and M Roncadin, and S Tumolo, and E Grigoletto

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008937 Mitomycins A group of methylazirinopyrroloindolediones obtained from certain Streptomyces strains. They are very toxic antibiotics used as ANTINEOPLASTIC AGENTS in some solid tumors. PORFIROMYCIN and MITOMYCIN are the most useful members of the group.
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002330 Carmustine A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed) BCNU,1,3-Bis(2-Chloroethyl)-1-Nitrosourea,BiCNU,FIVB,N,N'-Bis(2-Chloroethyl)-N-Nitrosourea,Nitrumon
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000230 Adenocarcinoma A malignant epithelial tumor with a glandular organization. Adenocarcinoma, Basal Cell,Adenocarcinoma, Granular Cell,Adenocarcinoma, Oxyphilic,Adenocarcinoma, Tubular,Adenoma, Malignant,Carcinoma, Cribriform,Carcinoma, Granular Cell,Carcinoma, Tubular,Adenocarcinomas,Adenocarcinomas, Basal Cell,Adenocarcinomas, Granular Cell,Adenocarcinomas, Oxyphilic,Adenocarcinomas, Tubular,Adenomas, Malignant,Basal Cell Adenocarcinoma,Basal Cell Adenocarcinomas,Carcinomas, Cribriform,Carcinomas, Granular Cell,Carcinomas, Tubular,Cribriform Carcinoma,Cribriform Carcinomas,Granular Cell Adenocarcinoma,Granular Cell Adenocarcinomas,Granular Cell Carcinoma,Granular Cell Carcinomas,Malignant Adenoma,Malignant Adenomas,Oxyphilic Adenocarcinoma,Oxyphilic Adenocarcinomas,Tubular Adenocarcinoma,Tubular Adenocarcinomas,Tubular Carcinoma,Tubular Carcinomas
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

A Veronesi, and U Tirelli, and E Galligioni, and M G Trovò, and D Crivellari, and M Donatella Magri, and M Roncadin, and S Tumolo, and E Grigoletto
Combination chemotherapy with BCNU, vincristine, mitomycin-C and prednisone in refractory breast carcinoma. A pilot study.
January 1984, Oncology,
A Veronesi, and U Tirelli, and E Galligioni, and M G Trovò, and D Crivellari, and M Donatella Magri, and M Roncadin, and S Tumolo, and E Grigoletto
Adriamycin (doxorubicin), vinblastine, and mitomycin C combination chemotherapy in refractory breast carcinoma.
October 1984, Cancer,
A Veronesi, and U Tirelli, and E Galligioni, and M G Trovò, and D Crivellari, and M Donatella Magri, and M Roncadin, and S Tumolo, and E Grigoletto
Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer.
April 1986, Cancer treatment reports,
A Veronesi, and U Tirelli, and E Galligioni, and M G Trovò, and D Crivellari, and M Donatella Magri, and M Roncadin, and S Tumolo, and E Grigoletto
Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer.
January 1986, Cancer chemotherapy and pharmacology,
A Veronesi, and U Tirelli, and E Galligioni, and M G Trovò, and D Crivellari, and M Donatella Magri, and M Roncadin, and S Tumolo, and E Grigoletto
Mitomycin C and vinblastine in advanced refractory breast cancer.
April 1989, Tumori,
A Veronesi, and U Tirelli, and E Galligioni, and M G Trovò, and D Crivellari, and M Donatella Magri, and M Roncadin, and S Tumolo, and E Grigoletto
MVP (mitomycin-C, vinblastine, cisplatin) salvage chemotherapy for relapsed and refractory metastatic breast cancer.
March 1997, Journal of the Formosan Medical Association = Taiwan yi zhi,
A Veronesi, and U Tirelli, and E Galligioni, and M G Trovò, and D Crivellari, and M Donatella Magri, and M Roncadin, and S Tumolo, and E Grigoletto
Mitomycin C is an inactive drug in the third-line treatment of hormone and chemotherapy refractory breast cancer.
September 1987, European journal of cancer & clinical oncology,
A Veronesi, and U Tirelli, and E Galligioni, and M G Trovò, and D Crivellari, and M Donatella Magri, and M Roncadin, and S Tumolo, and E Grigoletto
Chemotherapy with mitomycin C and vinblastine in pretreated metastatic breast cancer.
August 1993, Tumori,
A Veronesi, and U Tirelli, and E Galligioni, and M G Trovò, and D Crivellari, and M Donatella Magri, and M Roncadin, and S Tumolo, and E Grigoletto
Mitomycin C and vinblastine chemotherapy for advanced breast cancer.
September 1981, Cancer,
A Veronesi, and U Tirelli, and E Galligioni, and M G Trovò, and D Crivellari, and M Donatella Magri, and M Roncadin, and S Tumolo, and E Grigoletto
A pilot study of amiodarone with infusional doxorubicin or vinblastine in refractory breast cancer.
January 1995, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!